BRPI0418866A - métodos para solubilizar o latanoprost e para preparar uma solução oftálmica aquosa de latanoprost e solução resultante - Google Patents
métodos para solubilizar o latanoprost e para preparar uma solução oftálmica aquosa de latanoprost e solução resultanteInfo
- Publication number
- BRPI0418866A BRPI0418866A BRPI0418866-7A BRPI0418866A BRPI0418866A BR PI0418866 A BRPI0418866 A BR PI0418866A BR PI0418866 A BRPI0418866 A BR PI0418866A BR PI0418866 A BRPI0418866 A BR PI0418866A
- Authority
- BR
- Brazil
- Prior art keywords
- latanoprost
- ophthalmic solution
- solubilizing
- preparing
- solution
- Prior art date
Links
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 title abstract 5
- 229960001160 latanoprost Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 230000003381 solubilizing effect Effects 0.000 title abstract 3
- 229940110775 latanoprost ophthalmic solution Drugs 0.000 title abstract 2
- 239000000243 solution Substances 0.000 title abstract 2
- 229940054534 ophthalmic solution Drugs 0.000 abstract 3
- 239000002997 ophthalmic solution Substances 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 2
- IYGXEHDCSOYNKY-RZHHZEQLSA-N Dinoprost tromethamine Chemical compound OCC(N)(CO)CO.CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O IYGXEHDCSOYNKY-RZHHZEQLSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
MéTODOS PARA SOLUBILIZAR O LATANOPROST E PARA PREPARAR UMA SOLUçãO OFTáLMICA AQUOSA DE LATANOPROST E SOLUçãO RESULTANTE. A invenção refere-se a um método para solubilizar um agente ativo análogo da prostaglandina F2<244>, tal como latanoprost, e um método para preparar uma solução oftálmica aquosa a partir do latanoprost solubilizado para o tratamento de diversas afecções oculares. A presente invenção refere-se, além disso, a uma solução oftálmica aquosa que resulta do referido método, a qual se caracteriza por sua estabilidade química à temperatura ambiente, segurança, inocuidade e eficácia no tratamento do paciente. A nova solução oftálmica aquosa distingue-se porque seu valor farmacêutico radica no manejo de um veículo de fácil acesso que não somente permite a solubilidade do latanoprost, mas também favorece sua estabilidade química e uma maior tolerância do paciente à sua aplicação para o tratamento de seu padecimento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/MX2004/000034 WO2005115401A1 (es) | 2004-05-26 | 2004-05-26 | Un método para preparar una solución oftálmica de latanoprost y solución resultante |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0418866A true BRPI0418866A (pt) | 2007-11-20 |
Family
ID=35450648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0418866-7A BRPI0418866A (pt) | 2004-05-26 | 2004-05-26 | métodos para solubilizar o latanoprost e para preparar uma solução oftálmica aquosa de latanoprost e solução resultante |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US8293789B2 (pt) |
| EP (1) | EP1759702B1 (pt) |
| AR (1) | AR049113A1 (pt) |
| AT (1) | ATE419854T1 (pt) |
| BR (1) | BRPI0418866A (pt) |
| DE (1) | DE602004018990D1 (pt) |
| DK (1) | DK1759702T3 (pt) |
| ES (1) | ES2320770T3 (pt) |
| PL (1) | PL1759702T3 (pt) |
| PT (1) | PT1759702E (pt) |
| SI (1) | SI1759702T1 (pt) |
| WO (1) | WO2005115401A1 (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9579341B2 (en) | 2007-05-16 | 2017-02-28 | Johnson & Johnson Consumer Inc. | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
| US8609634B2 (en) * | 2007-05-16 | 2013-12-17 | Mcneil-Ppc, Inc. | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
| KR20100036361A (ko) * | 2007-07-11 | 2010-04-07 | 오프탈모파르마 에이쥐 | 프로스타글란딘 유도체 및 모노 치환, 하전된 베타-사이클로덱스트린의 복합체 |
| JP5668476B2 (ja) | 2007-10-08 | 2015-02-12 | オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物 |
| US8455547B2 (en) | 2008-02-05 | 2013-06-04 | Allergan, Inc. | Substituted cyclopentanes having prostaglandin activity |
| ITRM20080182A1 (it) * | 2008-04-07 | 2009-10-08 | Medivis S R L | Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma. |
| US9481856B2 (en) * | 2008-06-09 | 2016-11-01 | Bausch & Lomb Incorporated | Pharmaceutical formulations comprising stabilized polysaccharides and source of hydrogen peroxide |
| US10463677B2 (en) * | 2008-11-07 | 2019-11-05 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
| WO2010089355A1 (en) * | 2009-02-04 | 2010-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
| DE102009021372A1 (de) * | 2009-05-14 | 2010-11-18 | Ursapharm Arzneimittel Gmbh | Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung |
| EP2440185B1 (en) * | 2009-06-09 | 2015-04-08 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
| US8952051B2 (en) * | 2009-11-05 | 2015-02-10 | Allergan, Inc. | Ophthalmic formulations containing substituted gamma lactams and methods for use thereof |
| US20110136872A1 (en) * | 2009-12-09 | 2011-06-09 | Burk Robert M | Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof |
| WO2012021107A2 (en) * | 2010-08-12 | 2012-02-16 | Nanyang Technological University | A liposomal formulation for ocular drug delivery |
| DE102011108948A1 (de) * | 2011-07-29 | 2013-01-31 | Achim Göpferich | Wässrige, kolloidale Lösungen von lipophilen Substanzen,insbesondere Arzneistofflösungen |
| EP2567689A1 (en) * | 2011-09-12 | 2013-03-13 | Visiotact Pharma | Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid |
| US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
| ES2669446B1 (es) * | 2016-11-24 | 2019-03-13 | Saiz Manuel Munoz | Producto oftálmico |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| GR1009419B (el) * | 2017-11-07 | 2018-12-14 | Φαρματεν Αβεε | Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου |
| CN115350148A (zh) * | 2019-02-06 | 2022-11-18 | 特清公司 | 用于从包含络合剂的眼用制剂中去除防腐剂的系统和方法 |
| MX2021014220A (es) | 2019-08-07 | 2022-04-06 | Aneira Pharma Inc | Composiciones para el tratamiento de la perdida del cabello. |
| US12539302B2 (en) | 2019-08-07 | 2026-02-03 | Aneira Pharma, Inc. | Methods and compositions for the treatment of hair loss |
| ES3008008T3 (en) * | 2020-06-21 | 2025-03-21 | I Com Medical Gmbh | Use of high molecular weight hyaluronic acid as ocular transporting vehicle |
| CN115400074A (zh) * | 2021-05-27 | 2022-11-29 | 山东新时代药业有限公司 | 拉坦前列素滴眼液及其制备方法 |
| CO2024016594A1 (es) * | 2024-12-02 | 2024-12-09 | Espec Oftalmologicas S A | Colirio oftalmológico y/o vehículo farmacéutico indicado para el restablecimiento y la protección de la histéresis de la película lagrimal |
| GR1011143B (el) * | 2025-04-11 | 2026-03-02 | Ιουλια Τσετη | Οφθαλμικο διαλυμα προσταγλανδινης χωρις συντηρητικα |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU665287B2 (en) | 1992-12-21 | 1995-12-21 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
| US5631287A (en) | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
| US6646001B2 (en) * | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| CA2356912C (en) * | 1998-12-25 | 2009-02-24 | Ryuji Ueno | Pharmaceutical compositions for the treatment of ocular hypertension or glaucoma |
| JP2003531824A (ja) * | 2000-02-01 | 2003-10-28 | ケイマン ケミカル カムパニー，インク． | フルプロステノールおよび関連プロスタグランジンＦ２α類似体の内部１，１５−ラクトン、ならびに緑内障および眼高血圧の治療におけるそれらの使用 |
| US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| AR031135A1 (es) * | 2000-10-10 | 2003-09-10 | Upjohn Co | Composiciones de antibiotico topico para el tratamiento de infecciones oculares |
| US20030018079A1 (en) * | 2000-11-13 | 2003-01-23 | Richardson Helene | Treatment |
-
2004
- 2004-05-26 ES ES04748557T patent/ES2320770T3/es not_active Expired - Lifetime
- 2004-05-26 PT PT04748557T patent/PT1759702E/pt unknown
- 2004-05-26 DE DE602004018990T patent/DE602004018990D1/de not_active Expired - Lifetime
- 2004-05-26 AT AT04748557T patent/ATE419854T1/de active
- 2004-05-26 WO PCT/MX2004/000034 patent/WO2005115401A1/es not_active Ceased
- 2004-05-26 US US11/597,459 patent/US8293789B2/en not_active Expired - Fee Related
- 2004-05-26 PL PL04748557T patent/PL1759702T3/pl unknown
- 2004-05-26 DK DK04748557T patent/DK1759702T3/da active
- 2004-05-26 BR BRPI0418866-7A patent/BRPI0418866A/pt not_active IP Right Cessation
- 2004-05-26 EP EP04748557A patent/EP1759702B1/en not_active Expired - Lifetime
- 2004-05-26 SI SI200431084T patent/SI1759702T1/sl unknown
-
2005
- 2005-05-24 AR ARP050102140A patent/AR049113A1/es not_active Application Discontinuation
-
2011
- 2011-01-03 US US12/983,736 patent/US20110105605A1/en not_active Abandoned
- 2011-01-03 US US12/983,721 patent/US20110098354A1/en not_active Abandoned
- 2011-01-03 US US12/983,751 patent/US20110098355A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8293789B2 (en) | 2012-10-23 |
| US20110105605A1 (en) | 2011-05-05 |
| DK1759702T3 (da) | 2009-04-20 |
| EP1759702A1 (en) | 2007-03-07 |
| AR049113A1 (es) | 2006-06-28 |
| DE602004018990D1 (de) | 2009-02-26 |
| WO2005115401A1 (es) | 2005-12-08 |
| PL1759702T3 (pl) | 2009-06-30 |
| US20110098354A1 (en) | 2011-04-28 |
| US20080021101A1 (en) | 2008-01-24 |
| ES2320770T3 (es) | 2009-05-28 |
| EP1759702B1 (en) | 2009-01-07 |
| US20110098355A1 (en) | 2011-04-28 |
| PT1759702E (pt) | 2009-04-13 |
| ATE419854T1 (de) | 2009-01-15 |
| SI1759702T1 (sl) | 2009-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0513849A (pt) | implante ocular fabricado por um processo de extrusão dupla | |
| AR049113A1 (es) | Un metodo para preparar una solucion oftalmica y solucion oftalmica obtenida de un agente activo como latanoprost | |
| ES2052784T3 (es) | Procedimiento para la produccion de una composicion terapeutica administrable localmente para una enfermedad inflamatoria. | |
| BRPI0210707B8 (pt) | composição de solução para administração tópica no tratamento de distúrbios alérgicos ou inflamatórios do olho e do nariz e seu método de preparação | |
| BRPI0410786A (pt) | composição, uso da mesma, e, método de tratamento de um distúrbio de humor em um paciente | |
| DE69634414D1 (de) | Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie | |
| ECSP12012037A (es) | Composiciones oftálmicas no irritantes de iodopovidona | |
| BRPI0708038B8 (pt) | derivado de cumarina, composição farmacêutica e agente terapêutico para um distúrbio proliferativo celular | |
| CR10169A (es) | "uso de derivados de sulfamida heterociclica benzo-fusionada para disminuir lipidos y disminuir niveles de glucosa en la sangre" | |
| BR0111591A (pt) | Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes | |
| BR0209327A (pt) | Composição para tratamento de constipação induzida por drogas | |
| EA201300314A1 (ru) | Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство | |
| ATE491453T1 (de) | Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges | |
| RU2008127882A (ru) | Лечение пищевода барретта | |
| MXPA04004059A (es) | Metodo para tratar la depresion con compuestos agonistas receptores delta. | |
| Kringelholt et al. | Dual effect of prostaglandins on isolated intraocular porcine ciliary arteries | |
| MX2022016265A (es) | Composiciones terapeuticas de liberacion sostenida estable en solventes polares aproticos y metodos de preparacion de los mismos. | |
| BR0318395A (pt) | método para preparar uma solução aquosa de meloxicam e a solução aquosa resultante | |
| WO2024052880A1 (en) | Use of mdma for treatment of stress-related disorders | |
| Huang et al. | Nanocatalysts as fast and powerful medical intervention: Bridging cochlear implant therapies and advanced modelling using Hidden Markov Models (HMMs) for effective treatment of inner ear infections | |
| ITMI20090829A1 (it) | Composizioni oftalmiche per la riepitelizzazione, la cicatrizzazione, e la disinfezione dei tessuti oculari | |
| RU2002104498A (ru) | Применение тозилхлорамидов для лечения заболеваний кожи, слизистой оболочки, органов и тканей | |
| BR0209601A (pt) | Método para o tratamento da hipertensão ocular e do glaucoma | |
| AR033779A1 (es) | Compuestos utiles en la enfermedad de reflujo | |
| CA2901208A1 (en) | Topical ocular analgesic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. A61K 31/5575; A61P 27/02, 27/06 Ipc: A61K 31/5575 (2011.01), A61P 27/02 (2011.01), A61P |
|
| B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES. |
|
| B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |